

BMS-833923

Catalog No: tcsc1464



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1059734-66-5

Formula:

$C_{30}H_{27}N_5O$

Pathway:

Stem Cell/Wnt

Target:

Smo

Purity / Grade:

>98%

Solubility:

DMSO : 50 mg/mL (105.58 mM; Need ultrasonic)

Alternative Names:

XL-139

Observed Molecular Weight:

473.57

Product Description

BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothed with potential antineoplastic activity; inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC₅₀ of 21 nM.

IC₅₀ Value: 6-35 nM [1]


Target: Smoothed

SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.

in vitro: In vitro, BMS-833923 inhibits the expression of downstream effectors in the HH pathway (GLI1 and PTCH1) in cell lines that express wild-type SMO and those which express activated mutant forms of SMO (IC₅₀ values of 6-35 nM). In FACS-based binding assays, BMS-833923 inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC₅₀ of 21 nM [1].

in vivo: Pharmacodynamic studies show that BMS-833923 robustly inhibits HH pathway activity with along duration of action after a single oral dose in medulloblastoma and pancreatic carcinoma xenograft models. The pharmacodynamic effects of BMS-833923 observed in these models translate into tumor growth inhibition at well-tolerated doses [1].

Clinical trial: Dasatinib Combo With Smoothed (SMO) Antagonist (BMS-833923). Phase 2



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!